The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis

Stephen F. Badylak*, Sherry L. Voytik, Jack Henkin, Sandra Burke, Arthur A. Sasahara, Abby Simmons

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The efficacy of thrombolytic therapy may be limited by local availability of plasminogen near a poorly perfused thrombus. The purpose of this study was to determine if the local (i.e., clot site) administration of 0.5 mg glu-plasminogen (glu-plg) or 0.5 mg lysplasminogen (lys-plg) could safely increase the thrombolytic efficacy of a 30-min intraarterial injection of 3,500 U kg-1 of two-chain urokinase plasminogen activator (UK) in a dog model of arterial thrombosis. Thrombolysis was measured by monitoring the continuous decrement of 125 I-gamma emissions from a radiolabeled thrombus. Reflow was evaluated by a distally placed flowmeter and by direct visual examination. Forty-two dogs (mean weight 10.1 ± 1.9 kg) were randomly sorted into six groups of 7 each. The dogs in each group were given either saline plus saline (group 1), saline plus UK (group 2), glu-plg plus saline (group 3), glu-plg plus UK (group 4), lys-plg plus saline (group 5), or lys-plg plus UK (group 6) by selective arterial catheterization 60 min after formation of an occlusive thrombus. Ninety minutes following drug administration, all groups which received UK (groups 2, 4. and 6) showed greater lysis (p < 0.05) than the groups which received only saline or either glu-or lys-plg plus saline. Group 6, which received lys-plg plus UK, showed significantly greater lysis (34 ± 4%) than both group 2 (23 ± 2%), which received saline plus UK, and group 4 (19 ± 3%), which received glu-plg plus UK (p < 0.05). All dogs (7/7) in group 6 had reflow at 90 min whereas only 3/7 dogs had reflow in both groups 2 and 4. None of the dogs in groups 1, 3, or 5, which received only saline or either form of plasminogen, had reflow at 90 min. There were no changes in the prothrombin time, activated partial thromboplastin time, thrombin time, hematocrit, or platelet count in any of the six groups. We conclude that lys-plg can safely increase the thrombolytic efficacy of UK in a dog model of arterial thrombosis.

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalPathophysiology of Haemostasis and Thrombosis
Volume21
Issue number5
DOIs
StatePublished - 1991

Keywords

  • Dog model
  • Plasminogen
  • Thrombolysis
  • Urokinase

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis'. Together they form a unique fingerprint.

Cite this